Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety, tolerability and preliminary efficacy of
PQ912 in subjects with Mild Cognitive Impairment (MCI) due to Alzheimers Disease (AD) or mild
dementia due to AD.
Phase:
Phase 2
Details
Lead Sponsor:
Probiodrug AG Vivoryon Therapeutics N.V.
Collaborators:
Julius Clinical Julius Clinical, The Netherlands VU University Medical Center